Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404817 | 0.87 | POLB (0.48) | ROCK2ROCK1POLBCCR2SLC6A2 | |
| SCHEMBL5425443 | 0.79 | ROCK2 (0.70) | ROCK2ROCK1CCR2 | |
| SCHEMBL12628038 | 0.78 | POLB (0.52) | ROCK2ROCK1POLBCCR2TRPM5 | |
| SCHEMBL5419738 | 0.77 | ITGB3 (0.56) | ROCK2ROCK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1716563 | 0.77 | ROCK2 (0.62) | ROCK2ROCK1CCR2 | |
| SCHEMBL5424091 | 0.77 | P2RX7 (0.58) | ROCK2ROCK1POLBULK1 | |
| SCHEMBL7572076 | 0.75 | ROCK2 (0.55) | ROCK2ROCK1TRPM5 | |
| Hydrochloric Acid SCHEMBL5419088 | 0.75 | ROCK2 (0.59) | ROCK2ROCK1CCR2 | |
| SCHEMBL3536081 | 0.75 | POLB (0.52) | ROCK2ROCK1POLBCCR2SLC6A2 | |
| SCHEMBL5414994 | 0.73 | POLB (0.83) | ROCK2ROCK1POLBCCR2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885POLB 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.